Also Read: Sanofi’s Tolebrutinib Delays Disability Progression In Patients With Multiple Sclerosis, Data Shows. Sarclisa is the first anti-CD38 therapy in combination with standard-of-care VRd ...

Panacea Biotec has resolved a patent infringement lawsuit with Sanofi Healthcare concerning its EasySix hexavalent vaccine. Under the settlement, Sanofi will refrain from launching its Shan6 ...

Panacea Biotec has settled a patent infringement case with Sanofi Healthcare India over a hexavalent vaccine. Sanofi will not launch its Shan6 vaccine in India and will withdraw its opposition to ...

Panacea Biotec share price was locked in upper circuit in Tuesday's trading session after the company announced that it has entered into a settlement agreement with Sanofi Healthcare India over ...

Sept 16 (Reuters) - Sanofi (SASY.PA), opens new tab and partner AstraZeneca (AZN.L), opens new tab have received approval from the U.S. Food and Drug Administration for a manufacturing line for ...

Sanofi was ordered to pay €280,000 (£236,539) and Mdm Martin's victory could lead to hundreds of other French challenges. According to French newspaper Le Monde, the court declared Sanofi ...

Sanofi Consumer Healthcare has been listed on the BSE and NSE after its demerger from Sanofi India. Approved by the National Company Law Tribunal, this move aligns with Sanofi's global strategy.

Sanofi Consumer Healthcare India Limited has been listed on the BSE and National Stock Exchange (NSE). SCHIL’s demerger from Sanofi India Limited, executed under the Scheme of Arrangement, was ...

Sanofi will advance the development of AlphaMedix along with RadioMedix and Orano Med. Credit: ArDanMe/Shutterstock. Sanofi has signed an exclusive licensing agreement with RadioMedix and Orano Med to ...

In 2020, Sanofi invested nearly 500 million euros ($554 million) to build what it then called its Evolutive Vaccine Facility (EVF). The idea later evolved into including the manufacture of biologics.

Just four months after Sanofi bet $80 million in upfront cash on Fulcrum Therapeutics’ losmapimod, the program has ended in a phase 3 failure. The licensing deal with the Big Pharma was agreed ...

Sanofi agreed to pay up to 320 million euros ($352.4 million) to U.S. company RadioMedix and the biotechnology subsidiary of nuclear-fuel supplier Orano to license a potential treatment for rare ...